Piermont Capital Management’s Medifast MED Stock Holding History

Piermont Capital Management’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,980	Closed	-$477K	–	174
2018 Q2	$477K	Sell	2,980 -2,800	-48%	-$358K	0.15%	156
2018 Q1	$540K	Buy	+5,780	New	+$432K	0.18%	152
2015 Q2	–	Sell	-18,970	Closed	-$569K	–	240
2015 Q1	$569K	Buy	18,970 +6,400	+51%	+$203K	0.17%	145
2014 Q4	$422K	Hold	12,570	–	–	0.15%	115
2014 Q3	$413K	Buy	+12,570	New	+$386K	0.16%	111

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Piermont Capital Management's MED Position: Q3 2018 in Review

Piermont Capital Management sold out of Medifast (MED) in Q3 2018, closing a stake of 2,980 shares — an estimated $477K sold.

Piermont Capital Management first reported a position in MED in Q3 2014 and held it in 5 quarters. The position peaked at $569K in Q1 2015. 266 funds tracked by Wall St. Rank hold MED as of Q3 2018.

Piermont Capital Management reported no remaining Medifast position as of Q3 2018 after selling out during the quarter.
Piermont Capital Management sold 2,980 Medifast shares in Q3 2018, an estimated $477K.
Piermont Capital Management first reported a position in Medifast in Q3 2014 and held it in 5 quarters.
Piermont Capital Management's Medifast position peaked at $569K in Q1 2015.
266 funds tracked by Wall St. Rank held Medifast as of Q3 2018.

Based on Piermont Capital Management's 13F filing for Q3 2018, filed 6 Nov 2018.